➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: January 27, 2021

DrugPatentWatch Database Preview

QMIIZ ODT Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Qmiiz Odt, and what generic alternatives are available?

Qmiiz Odt is a drug marketed by Tersera and is included in one NDA. There is one patent protecting this drug.

This drug has one patent family member in one country.

The generic ingredient in QMIIZ ODT is meloxicam. There are twenty-two drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the meloxicam profile page.

US ANDA Litigation and Generic Entry Outlook for Qmiiz Odt

A generic version of QMIIZ ODT was approved as meloxicam by CIPLA on July 19th, 2006.

  Start Trial

Summary for QMIIZ ODT
International Patents:1
US Patents:1
Suppliers / Packagers: 1
Formulation / Manufacturing:see details
DailyMed Link:QMIIZ ODT at DailyMed
Drug patent expirations by year for QMIIZ ODT
Pharmacology for QMIIZ ODT

US Patents and Regulatory Information for QMIIZ ODT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Tersera QMIIZ ODT meloxicam TABLET, ORALLY DISINTEGRATING;ORAL 211210-001 Oct 19, 2018 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Tersera QMIIZ ODT meloxicam TABLET, ORALLY DISINTEGRATING;ORAL 211210-002 Oct 19, 2018 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.